Markets:

Overview

News

Currencies

International

Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

71.54 -0.50 (-0.69%)

Streaming Delayed Price Updated: 11:42 AM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 Next >

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. ↗

March 03, 2025

This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1.

Via Investor's Business Daily

Why Structure Therapeutics Stock Was Stumbling This Week ↗

February 14, 2025

Via The Motley Fool

AI Pharma: 2 Paths to AI-Powered Drug Investment

January 28, 2025

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Via MarketBeat

Topics Artificial Intelligence

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Peering Into Structure Therapeutics's Recent Short Interest ↗

July 15, 2024

Via Benzinga

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst ↗

January 06, 2025

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Via Benzinga

Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗

December 18, 2024

Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.

Via Investor's Business Daily

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

December 18, 2024

Via Benzinga

Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗

December 16, 2024

The weight-loss drugs space continues to heat up. Here's the latest news from the segment.

Via Investor's Business Daily

Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry? ↗

November 22, 2024

Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.

Via Investor's Business Daily

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 16, 2024

Via Benzinga

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗

October 14, 2024

The analyst is closely watching MariTide, a potential monthly injection to treat obesity.

Via Investor's Business Daily

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗

October 04, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Via Investor's Business Daily

Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday ↗

September 30, 2024

Via Benzinga

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO ↗

September 26, 2024

The company is working on a drug that mimics apelin, which is released following exercise.

Via Investor's Business Daily

Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review ↗

September 13, 2024

The major indexes reclaimed key levels and many leaders flashed buy signals.

Via Investor's Business Daily

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Via Investor's Business Daily

3 Promising Biotech Stocks for the Long-Term: August 2024 ↗

August 13, 2024

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.

Via InvestorPlace

GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q2 2024 ↗

August 09, 2024

GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

3 Biotech Stocks That Could Make Your Summer Unforgettable ↗

July 30, 2024

If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.

Via InvestorPlace

Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon. ↗

July 22, 2024

Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.

Via The Motley Fool

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review ↗

July 19, 2024

The Nasdaq tumbled amid chip woes.

Via Investor's Business Daily

Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 17, 2024

Via Benzinga

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? ↗

July 17, 2024

Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest...

Via Benzinga

ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

July 17, 2024

Via Benzinga

The 3 Most Undervalued Biotech Stocks to Buy in July 2024 ↗

July 12, 2024

There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment.

Via InvestorPlace

The 3 Smartest Biotech Stocks to Buy With $5K Right Now ↗

June 28, 2024

With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.

Via InvestorPlace

Could Structure Therapeutics Become the Next Novo Nordisk? ↗

June 17, 2024

Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.

Via The Motley Fool

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar ↗

June 14, 2024

The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.

Via Investor's Business Daily

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

Headline News about Structure Therapeutics Inc. - American Depositary Shares

Starting at $3.75/week.

Subscribe Today